Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers

Targeted therapies against basal-like breast tumors, which are typically ‘triple-negative breast cancers (TNBCs)’, remain an important unmet clinical need. Somatic TP53 mutations are the most common genetic event in basal-like breast tumors and TNBC. To identify additional drivers and possible drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfefferle, Adam D., Agrawal, Yash N., Koboldt, Daniel C., Kanchi, Krishna L., Herschkowitz, Jason I., Mardis, Elaine R., Rosen, Jeffrey M., Perou, Charles M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958311/
https://www.ncbi.nlm.nih.gov/pubmed/27149990
http://dx.doi.org/10.1242/dmm.025239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958311/
https://www.ncbi.nlm.nih.gov/pubmed/27149990
http://dx.doi.org/10.1242/dmm.025239

Ejemplares similares